Fed. Circ. Upholds Eli Lilly's Alimta Vitamin Regimen IP

The Federal Circuit on Friday affirmed decisions from the Patent Trial and Appeal Board upholding a patent protecting the vitamin regimen for Eli Lilly & Co.'s cancer treatment Alimta, while refusing...

Already a subscriber? Click here to view full article